LianBio last reported quarterly results on Nov 13, 2023, for Q3 FY2023 (the quarter ended Sep 30, 2023): diluted EPS of -$0.22. It usually reports 41–45 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 13, 2023
44 days after quarter end
|
Q3 FY2023
ended Sep 30, 2023
|
—
|
-24
-9.8%
|
-0.22
-10.0%
|
|
Aug 14, 2023
45 days after quarter end
|
Q2 FY2023
ended Jun 30, 2023
|
—
|
-22
+49.0%
|
-0.20
+48.7%
|
|
May 11, 2023
41 days after quarter end
|
Q1 FY2023
ended Mar 31, 2023
|
—
|
-24
+13.3%
|
-0.22
+15.4%
|
|
Nov 10, 2022
41 days after quarter end
|
Q3 FY2022
ended Sep 30, 2022
|
—
|
-22
-67.0%
|
-0.20
|
|
Aug 11, 2022
42 days after quarter end
|
Q2 FY2022
ended Jun 30, 2022
|
—
|
-42
|
-0.39
|
|
May 12, 2022
42 days after quarter end
|
Q1 FY2022
ended Mar 31, 2022
|
—
|
-28
|
-0.26
|
|
Dec 9, 2021
70 days after quarter end
|
—
ended Sep 30, 2021
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIANY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1831283
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.